Vitamin C showed unexpected signs of benefit in people at risk of blood cancer.
Date:
October 3, 2026 system. In a phase 2 trial of people with precancerous or low risk blood cancers, daily vitamin C did not slow abnormal cell growth, but it was linked to favorable changes in inflammation and fewer serious complications. An exploratory follow up also found fewer deaths among participants taking vitamin C than among those receiving placebo.
Share:
FULL STORY
Vitamin C can increase the activity of cellular proteins known as TET enzymes, which help regulate whether certain genes are switched on or off. Reduced TET enzyme activity is a common feature in some blood cancers, prompting researchers to investigate whether vitamin C supplements might benefit people at risk of developing these diseases.
The findings come from a phase 2 clinical trial published online by Wiley in CANCER, a peer-reviewed journal of the American Cancer Society.
Testing Vitamin C in People at Risk of Blood Cancer
The randomized, double-blind, placebo-controlled EVITA trial included 109
The randomized, double-blind, placebo-controlled EVITA trial included 109 participants in Denmark and the United States. All had either a blood disorder with the potential to become cancerous or a low-risk form of blood cancer.
At the beginning of the study, 55 participants were randomly assigned to take oral vitamin C (1,000 mg/day), while 54 received a placebo. Treatment continued for 12 months.
The main outcome researchers were looking for was whether vitamin C affected the growth rate of precancerous or cancerous cells. On that measure, the vitamin C and placebo groups were similar.
Researchers did observe other differences
However, researchers did observe other differences. People taking vitamin C showed changes in inflammatory signaling that align with better outcomes. They also experienced fewer cases of anemia, pneumonia, acute aseptic arthritis, and internal bleeding, although gastrointestinal problems were more common in the vitamin C group.
At a median follow-up of 33.6 months (nearly 3 years) in the intention-to-treat population, 35 participants had died. Of those deaths, 24 occurred in the placebo group and 11 occurred in the vitamin C group.
An exploratory analysis found that participants assigned to vitamin C were more likely to survive during follow-up than those who received placebo. Because this was an exploratory finding, researchers say it must be tested and confirmed in a larger phase 3 clinical trial before firm conclusions can be drawn.
The EVITA trial gives us a strong rationale
“The EVITA trial gives us a strong rationale to continue exploring if and how vitamin C might benefit people with certain pre-cancer or early-stage blood cancers. More work is needed but we are cautiously optimistic that these findings could inform future strategies to intercept leukemia development,” said co-senior author Peter A. Jones, PhD, DSc (hon), of Van Andel Institute, in Grand Rapids, Michigan. Jones is co-leader of the Van Andel Institute-Stand Up To Cancer (VAI-SU2C) Epigenetics Dream Team, which led the EVITA trial.
Researchers emphasized that the results are encouraging but are not yet strong enough to support new treatment recommendations.
“We are encouraged by our findings and what they ultimately could mean for people with these early-stage blood disorders. Although it is too soon to make recommendations based on our results, we are hopeful that a larger study will give us more definitive answers,” added co-senior author Kirsten Grønbæk, MD, PhD, of Rigshospitalet, Copenhagen University Hospital in Denmark. Grønbæk is a longtime member of the VAI-SU2C Epigenetics Dream Team.
Materials provided by Wiley. Note: Content may be edited for style and length.
- Stine Ulrik Mikkelsen, Ali Al‐Mousawi, Amalie Bach Puglisi, Anders Pommer Vallentin, Astrid Østergaard Mortensen, Zachary Madaj, Toshinori Hinoue, Heidi Naomi Ottesen, Jakob Schmidt Jespersen, Linn Gillberg, Morten Tulstrup, Niels Richard Hansen, Jakob Werner Hansen, Mette Klarskov Andersen, Stacey Lyn Thomas, Christine Isaguirre, Ryan Sheldon, Marie Adams, Ryan Burgos, Stephen Baylin, Bo Kok Mortensen, Casey Lee O’Connell, Marianne Tang Severinsen, Peter William Laird, Jens Lykkesfeldt, Peter Jones, Kirsten Grønbæk. Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial. Cancer, 2026; 132 (19) DOI: 10.1002/cncr.70549
Wiley. “Vitamin C linked to fewer deaths in blood disorder trial.” ScienceDaily. ScienceDaily, 3 October 2026. <www.sciencedaily.com/releases/2026/09/260930225454.htm>.
Wiley. (2026, October 3). Vitamin C linked to fewer deaths in blood disorder trial. ScienceDaily. Retrieved October 3, 2026 from www.sciencedaily.com/releases/2026/09/260930225454.htm
Wiley. “Vitamin C linked to fewer deaths in blood disorder trial.” ScienceDaily. www.sciencedaily.com/releases/2026/09/260930225454.htm (accessed October 3, 2026).
RELATED STORIES
